BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 34390437)

  • 1. Evaluation of acute and chronic nephrotoxicity in patients received cisplatin-based chemotherapy: has anything changed over time?
    Kamacı ŞÇ; Koçak G; Yeşilova A; Cihan Ş
    Int Urol Nephrol; 2022 May; 54(5):1085-1090. PubMed ID: 34390437
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Electrolytes supplementation can decrease the risk of nephrotoxicity in patients with solid tumors undergoing chemotherapy with cisplatin.
    Minzi OMS; Lyimo TE; Furia FF; Marealle AI; Kilonzi M; Bwire GM; Malichewe C
    BMC Pharmacol Toxicol; 2020 Sep; 21(1):69. PubMed ID: 32967726
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk factors for cisplatin-induced nephrotoxicity and potential of magnesium supplementation for renal protection.
    Kidera Y; Kawakami H; Sakiyama T; Okamoto K; Tanaka K; Takeda M; Kaneda H; Nishina S; Tsurutani J; Fujiwara K; Nomura M; Yamazoe Y; Chiba Y; Nishida S; Tamura T; Nakagawa K
    PLoS One; 2014; 9(7):e101902. PubMed ID: 25020203
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of cisplatin-induced nephrotoxicity when using conventional versus short hydration in gastric cancer-a retrospective study.
    Aoyama T; Tsunoda T; Kato H; Hagino A; Furutani R; Ito K; Yoshioka H; Nakamura M; Hiraide M; Kawakami K; Kobayashi K; Suzuki K; Ichimura T; Yamaguchi K; Hama T
    J Chemother; 2020 May; 32(3):144-150. PubMed ID: 31960769
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of cisplatin nephrotoxicity with patient characteristics and cisplatin administration methods.
    Stewart DJ; Dulberg CS; Mikhael NZ; Redmond MD; Montpetit VA; Goel R
    Cancer Chemother Pharmacol; 1997; 40(4):293-308. PubMed ID: 9225947
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk Factors for Cisplatin-Induced Nephrotoxicity: A Multicenter Retrospective Study.
    Miyoshi T; Uoi M; Omura F; Tsumagari K; Maesaki S; Yokota C
    Oncology; 2021; 99(2):105-113. PubMed ID: 32966986
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Absence of effect of SLC22A2 genotype on cisplatin-induced nephrotoxicity in oesophageal cancer patients receiving cisplatin and 5-fluorouracil: report of results discordant with those of earlier studies.
    Hinai Y; Motoyama S; Niioka T; Miura M
    J Clin Pharm Ther; 2013 Dec; 38(6):498-503. PubMed ID: 24102360
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Protective effect of magnesium preloading on cisplatin-induced nephrotoxicity: a retrospective study.
    Yoshida T; Niho S; Toda M; Goto K; Yoh K; Umemura S; Matsumoto S; Ohmatsu H; Ohe Y
    Jpn J Clin Oncol; 2014 Apr; 44(4):346-54. PubMed ID: 24503028
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nephrotoxicity of cisplatin combination chemotherapy in thoracic malignancy patients with CKD risk factors.
    Sato K; Watanabe S; Ohtsubo A; Shoji S; Ishikawa D; Tanaka T; Nozaki K; Kondo R; Okajima M; Miura S; Tanaka J; Sakagami T; Koya T; Kagamu H; Yoshizawa H; Narita I
    BMC Cancer; 2016 Mar; 16():222. PubMed ID: 26979596
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A case-control study analyzing mannitol dosing for prevention of cisplatin-induced acute nephrotoxicity.
    Dhillon P; Amir E; Lo M; Kitchlu A; Chan C; Cochlin S; Yip P; Chen E; Lee R; Ng P
    J Oncol Pharm Pract; 2019 Jun; 25(4):875-883. PubMed ID: 29722605
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lower blood pressure and risk of cisplatin nephrotoxicity: a retrospective cohort study.
    Komaki K; Kusaba T; Tanaka M; Kado H; Shiotsu Y; Matsui M; Shiozaki A; Nakano H; Ishikawa T; Fujiwara H; Konishi H; Itoh Y; Matoba S; Tamagaki K
    BMC Cancer; 2017 Feb; 17(1):144. PubMed ID: 28219368
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of renal function using the level of neutrophil gelatinase-associated lipocalin is not predictive of nephrotoxicity associated with cisplatin-based chemotherapy.
    Kos FT; Sendur MA; Aksoy S; Celik HT; Sezer S; Civelek B; Yaman S; Zengin N
    Asian Pac J Cancer Prev; 2013; 14(2):1111-4. PubMed ID: 23621196
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Short hydration regimen with magnesium supplementation prevents cisplatin-induced nephrotoxicity in lung cancer: a retrospective analysis.
    Yamaguchi T; Uozu S; Isogai S; Hayashi M; Goto Y; Nakanishi T; Imaizumi K
    Support Care Cancer; 2017 Apr; 25(4):1215-1220. PubMed ID: 27966021
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hydration with 15 mEq Magnesium Is Effective at Reducingthe Risk for Cisplatin-induced Nephrotoxicity in Patients Receiving Cisplatin (≥50 mg/m2) Combination Chemotherapy.
    Yamamoto Y; Watanabe K; Tsukiyama I; Yabushita H; Matsuura K; Wakatsuki A
    Anticancer Res; 2016 Apr; 36(4):1873-7. PubMed ID: 27069173
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Systematic Review of Strategies to Prevent Cisplatin-Induced Nephrotoxicity.
    Crona DJ; Faso A; Nishijima TF; McGraw KA; Galsky MD; Milowsky MI
    Oncologist; 2017 May; 22(5):609-619. PubMed ID: 28438887
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Short hydration regimen and nephrotoxicity of intermediate to high-dose cisplatin-based chemotherapy for outpatient treatment in lung cancer and mesothelioma.
    Tiseo M; Martelli O; Mancuso A; Sormani MP; Bruzzi P; Di Salvia R; De Marinis F; Ardizzoni A
    Tumori; 2007; 93(2):138-44. PubMed ID: 17557559
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cisplatin Nephrotoxicity and Longitudinal Growth in Children With Solid Tumors: A Retrospective Cohort Study.
    Jiménez-Triana CA; Castelán-Martínez OD; Rivas-Ruiz R; Jiménez-Méndez R; Medina A; Clark P; Rassekh R; Castañeda-Hernández G; Carleton B; Medeiros M;
    Medicine (Baltimore); 2015 Aug; 94(34):e1413. PubMed ID: 26313789
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Saline, mannitol, and furosemide hydration in acute cisplatin nephrotoxicity: a randomized trial.
    Santoso JT; Lucci JA; Coleman RL; Schafer I; Hannigan EV
    Cancer Chemother Pharmacol; 2003 Jul; 52(1):13-8. PubMed ID: 12719883
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Correlation between magnesium pre-loading and cisplatin-induced nephrotoxicity in 5-fluorouracil/cisplatin combination therapy for esophageal cancer.
    Sugisaki T; Aoyama T; Kawakami K; Yokokawa T; Kobayashi K; Suzuki W; Ogura M; Ichimura T; Chin K; Yamaguchi K; Hanaoka S; Hayashi H; Yamaguchi M
    Pharmazie; 2022 Feb; 77(2):85-88. PubMed ID: 35209969
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A retrospective evaluation of furosemide and mannitol for prevention of cisplatin-induced nephrotoxicity.
    Mach CM; Kha C; Nguyen D; Shumway J; Meaders KM; Ludwig M; Williams-Brown MY; Anderson ML
    J Clin Pharm Ther; 2017 Jun; 42(3):286-291. PubMed ID: 28276070
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.